摘要
来那替尼(neratinib,商品名NERLYNX)为Puma生物科技公司开发的HER酪氨酸激酶抑制剂(tyrosine kinase inhibitor,TKI)。2017年7月17日,FDA批准其用于早期HER_2阳性乳腺癌的延长性辅助治疗(extended adjuvant therapy)。对于该类型的癌症,来那替尼为首个延长性辅助治疗药物,可降低HER_2阳性乳腺癌的相关复发风险。笔者就来那替尼的研发历程、基本信息、作用机制、药动学、药效学、临床试验及应用等研发动态作一概述,以期能为医院临床用药起到指导作用。
Neratinib （trade name NERLYNX） is an oral HER tyrosine kinase inhibitor （TKI） developed by Puma Biotechnology Inc.On July 17,2017,the U.S.Food and Drug Administration approved neratinib for extended adjuvant treatment of early-stage and HER2-positive breast cancer.NERLYNX is the first drug for extended adjuvant therapy and has a role of reducing the risk of recurrence in HER2-positive breast cancer.The development,process,properties,mechanism,pharmacokinetics,pharmacodynamics,clinical trials and applications of neratinib were reviewed in this article in order to guide its clinical application.
出处
《临床药物治疗杂志》
2017年第8期10-14,共5页
Clinical Medication Journal
基金
国家自然科学基金(81230077)
